✦ LIBER ✦

The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

✍ Scribed by Josefin-Beate Holz

Book ID: 116929172
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 354 KB
Volume: 46
Category: Article
ISSN: 1473-0502
DOI: 10.1016/j.transci.2012.03.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The active conformation of von Willebran

The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission

✍ E. GROOT; R. FIJNHEER; S. A. E. SEBASTIAN; PH. G. DE GROOT; P. J. LENTING 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

Dissociation between the level of von Wi

Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura

✍ Carolyn E. Snider; Jane C. Moore; Theodore E. Warkentin; Clara N. Finch; Catheri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract Decreased von Willebrand factor (VWF)‐cleaving protease activity (<5%) has been implicated in patients with congenital thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (Upshaw‐Schulman syndrome) and associated with mutations within the __ADAMTS13__ gene. In this report, we

Clinical usefulness of a functional assa

Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura

✍ M.E. Rick; H. Austin; S.F. Leitman; D.M. Krizek; D.L. Aronson 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views